

Liver function monitoring scheme with Valdoxan

☐ Valdoxan 25 mg

☐ Before Initiation of 25mg

ALTU/L

ASTU/L

☐ Week 3

ALTU/L

ASTU/L

☐ Week 6

ALTU/L

ASTU/L

☐ Week 12

ALTU/L

ASTU/L

☐ Week 24

ALTU/L

ASTU/L

Please perform a test at any time if clinically justified.

☐ In case of dose increase **at 50mg**, restart the monitoring scheme.

☐ Initiation of 50mg

ALTU/L

ASTU/L

☐ Week 3

ALTU/L

ASTU/L

☐ Week 6

ALTU/L

ASTU/L

☐ Week 12

ALTU/L

ASTU/L

☐ Week 24

ALTU/L

Please perform a test at any time if clinically justified.

Patient name: _____

Date of initiation: _____

Serum transaminases (ALT, AST)

Symptoms or any sign of potential liver injury*

ALT and/or AST
> 3 times the upper limit of normal

ALT and/or AST
≤ 3 times the upper limit of normal

Normal

Symptoms or any sign of potential liver injury*

No symptom or sign of liver injury
Repeat liver function tests within 48 hours

ALT and/or AST
> 3 times the upper limit of normal

ALT and/or AST
≤ 3 times the upper limit of normal

 **Discontinue the treatment**

- Liver function tests (including transaminases) should be performed

 **Discontinue the treatment**

- Repeat liver function tests regularly until serum transaminases return to normal



Continue the treatment

- Follow the time schedule for liver monitoring tests

* Such as dark urine, light coloured stools, yellow skin/eyes, pain in the upper right belly, sustained new-onset and unexplained fatigue